secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001104659-24-080022
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel reports preliminary Q2 2024 IGALMI net revenue of $1.1M, up 90% QoQ
---------------------------------------------------------------------------

- Preliminary Q2 2024 net revenue from IGALMI approximately $1.1M, up 90% from Q1 2024 and 141% from Q2 2023.
- Growth driven by increased contracting with psychiatric clinics and behavioral health facilities via small commercial team.
- CEO cites potential for at-home expansion if BXCL501 approved, targeting estimated 23M annual agitation episodes.
- Full Q2 2024 financial results and business update to be discussed on a future earnings call (date TBD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/0001104659-24-080022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465924080022/tm2419377d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-080022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer